Optimization of therapeutic procedure during LDL-apheresis - verification of the computerized model in clinical practice

被引:3
|
作者
Masin, Vladimir [1 ]
Blaha, Milan
Stransky, Pravoslav
Blaha, Vladimir
Cermanova, Melanie
Maly, Radovan
Zajic, Jiri
机构
[1] Charles Univ Prague, Fac Med, Hradec Kralove, Czech Republic
[2] Fac Hosp, Hradec Kralove, Czech Republic
关键词
LDL apheresis; familial hypercholesterolemia; atherosclerosis; immunoadsorption;
D O I
10.1016/j.transci.2006.10.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
LDL-apheresis is a very effective method in the treatment of resistant hypercholesterolemia when other therapies fail. To maximize the efficacy of the use of LDL-absorbers, we created a computerized model. The aim of this study is to verify it in clinical use. Patients and methods: A therapeutic technique of immunoadsorption was used, applying a pair of Lipopak columns (Pocard, Russia). Plasma was separated by a continuous-flow plasma separator (Cobe Spectra, USA); adsorption was controlled by adsorption-desorption equipment Adasorb (Medicap, Germany). 494 LDL-apheresis procedures had been performed in nine patients with primary hypercholesterolemia in the earlier, initial study; 47 other procedures (202 therapeutic cycles) were used in this verification study. The program for procedure planning uses Microsoft Excel for Windows. Complex metabolism of the LDL-cholesterol was neglected (owing to the short-time period of the procedure) and the procedure calculated as continuous filtration. The input enterer into the program includes basic patient data (mass, height, sex and initial plasma LDL level in mmol/L). Results: The results show a very good match between calculated levels and the real laboratory results in most procedures, but in some procedures we observed minor differences (0.05 mmol/L), which was caused by procedure adjustments due to technical reasons. However, some methodological and medical details must be carefully observed (initial cholesterol level, correct calculation of plasma volume, and the precise capacity of adsorbers that must not be overshot); as they influence the correct match between calculated and real results significantly. Conclusions: Although our software uses a fairly simplified model of the LDL-cholesterol kinetics during the LDL-apheresis, it is providing a great aid in the procedure planning. It is also suitable for practical use because it only requires a few commonly used and readily available input values. 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:39 / 45
页数:7
相关论文
共 50 条
  • [21] Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia
    Mabuchi, H
    Higashikata, T
    Kawashiri, M
    TRANSFUSION AND APHERESIS SCIENCE, 2004, 30 (03) : 233 - 243
  • [22] Clinical trial of LDL-apheresis therapy by direct hemoperfusion column: Multicenter trial
    Tasaki, H
    Nihei, S
    Hirakawa, N
    Toyokawa, T
    Nakashima, Y
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (05) : E17 - E17
  • [23] LDL-APHERESIS AND IMPROVEMENT IN THE CORONARY ATHEROSCLEROSIS OF FAMILIAL HYPERCHOLESTEROLEMIA - CORRELATION OF COMPUTERIZED QUANTITATIVE CORONARY ANGIOGRAPHY WITH AUTOPSY FINDINGS
    KOGA, N
    SATOH, T
    WATANABE, K
    KOHCHI, K
    IWATA, Y
    MINAMI, H
    BIOMATERIALS ARTIFICIAL CELLS AND IMMOBILIZATION BIOTECHNOLOGY, 1991, 19 (01): : 37 - 52
  • [24] COMPLEMENT ACTIVATION AND DEPLETION DURING LDL-APHERESIS BY HEPARIN-INDUCED EXTRACORPOREAL LDL-PRECIPITATION (HELP)
    WURZNER, R
    SCHUFFWERNER, P
    FRANZKE, A
    NITZE, R
    OPPERMANN, M
    ARMSTRONG, VW
    EISENHAUER, T
    SEIDEL, D
    GOTZE, O
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1991, 21 (03) : 288 - 294
  • [25] Clinical utility of LDL-apheresis in the treatment of sudden hearing loss:: a prospective, randomized study
    Suckfüll, M
    Thiery, J
    Schorn, K
    Kastenbauer, E
    Seidel, D
    ACTA OTO-LARYNGOLOGICA, 1999, 119 (07) : 763 - 766
  • [26] The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis
    Abe, Takaya
    Matsuo, Hidenori
    Abe, Ryuzo
    Abe, Shinji
    Asada, Hiroaki
    Ashida, Akira
    Baba, Akiyasu
    Eguchi, Kei
    Eguchi, Yutaka
    Endo, Yoshihiro
    Fujimori, Yoshihiro
    Furuichi, Kengo
    Furukawa, Yutaka
    Furuya, Mayumi
    Furuya, Tomoki
    Hanafusa, Norio
    Hara, Wataru
    Harada-Shiba, Mariko
    Hasegawa, Midori
    Hattori, Noriyuki
    Hattori, Motoshi
    Hidaka, Sumi
    Hidaka, Toshihiko
    Hirayama, Chika
    Ikeda, Shigaku
    Imamura, Hideaki
    Inoue, Kazuaki
    Ishizuka, Keita
    Ishizuka, Kiyonobu
    Ito, Takafumi
    Iwamoto, Hitomi
    Izaki, Syoko
    Kagitani, Maki
    Kaneko, Shuzo
    Kaneko, Naoto
    Kanekura, Takuro
    Kitagawa, Kiyoki
    Kusaoi, Makio
    Lin, Youwei
    Maeda, Takeshi
    Makino, Hisashi
    Makino, Shigeki
    Matsuda, Kenichi
    Matsugane, Takao
    Minematsu, Yusuke
    Mineshima, Michio
    Miura, Kenichiro
    Miyamoto, Katsuichi
    Moriguchi, Takeshi
    Murata, Mayumi
    THERAPEUTIC APHERESIS AND DIALYSIS, 2021, 25 (06) : 728 - 876
  • [27] Clinical and instrumental evaluation of LDL-apheresis on 11 patients with a 10 years follow-up
    Parasyris, I
    Galetti, C
    Mussoni, C
    Panourgia, MP
    Sangiorgi, Z
    Conte, R
    Gaddi, A
    ATHEROSCLEROSIS, 1999, 144 : 199 - 200
  • [28] LACK OF PLASMA-LIPID PEROXIDATION DURING LDL-APHERESIS BY HEPARIN-INDUCED EXTRACORPOREAL LDL-PRECIPITATION
    WIELAND, E
    SCHETTLER, V
    CREUTZFELDT, C
    KICKBUSCH, H
    SCHUFFWERNER, P
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1995, 25 (11) : 838 - 842
  • [29] LDL hemoperfusion - A new procedure for LDL apheresis: First clinical application of an LDL adsorber compatible with human whole blood
    Bosch, T
    Schmidt, B
    Kleophas, W
    Gillen, C
    Otto, V
    PasslickDeetjen, J
    Gurland, HJ
    ARTIFICIAL ORGANS, 1997, 21 (09) : 977 - 982
  • [30] Changes of autoantibodies against oxidatively modified low density lipoproteins during long-term LDL-apheresis
    Turk, Z
    Mrzljak, V
    Turk, N
    Metelko, Z
    DIABETES NUTRITION & METABOLISM, 1999, 12 (06) : 413 - 417